Aerie Pharmaceuticals Prices Upsized Offering

Aerie Pharmaceuticals said it has priced its registered underwritten public offering of $75 million of shares at $53.75 per share. The offering was upsized by $25 million and is in addition to the $50 million of shares sold through an at-the-market program and expected to be issued around May 31.

Proceeds will be used for general corporate purposes, including the expansion of its commercialization programs in North America for both Rhopressa and Roclatan, potential preclinical and clinical activities for pipeline therapy and delivery technology, clinical and commercialization efforts beyond North America, and manufacturing. Proceeds may also be used for working capital and potentially for the expansion of external business development programs.

Leave a Comment